
NYSE: CRLCharles River Laboratories
Charles River agrees to acquire Frontage bioanalysis unit for $470 million
The deal includes up to $75 million of additional payments and is expected to close in the first half of 2027, subject to approvals.
- US stocks
- Mergers & acquisitions
